Overview of Грофибрат

Quick Facts

Property	Description
Active ingredient	Fenofibrate (Prodrug)
Form	Oral tablets and capsules (specialized formulations)
Pharmacological class	Fibric acid derivatives (Fibrates)
General purpose	Lipid-regulating agent (Corrects abnormal fat levels)
Origin/Type	Synthetic, Prescription-only

Classification and Primary Purpose

Грофибрат is a synthetic, prescription-only medication with the active ingredient Fenofibrate, clinically recognized as a lipid-regulating agent used to manage abnormal fat levels, or dyslipidemia, in the bloodstream. This compound belongs to the pharmacological class of fibric acid derivatives, commonly known as fibrates. The general purpose of this therapy is to address an unhealthy lipid profile that involves elevated circulating fats. Fenofibrate is used to reduce high cholesterol and triglycerides in the blood. This signifies that the medicine is fundamentally designed to aid in the rebalancing of circulating fats, addressing the underlying condition.

Composition and Pharmaceutical Form

The active substance in Грофибрат is Fenofibrate, a single-ingredient product administered via the oral route in the form of tablets or capsules. Fenofibrate is designated as a prodrug; it is chemically inactive upon ingestion and must be rapidly converted into its sole working form, Fenofibric acid, to achieve its therapeutic effect. Specialized solid dosage forms, such as micronized or nanocrystal formulations, are used to enhance absorption and ensure optimal bioavailability of the active component. Грофибрат is positioned as a trusted prescription-only option for adults requiring significant modification of their lipid parameters.

Грофибрат: What is its General Benefit?

The general benefit of Грофибрат lies in its capacity to actively rebalance the overall lipid profile. This action involves promoting the reduction of triglycerides and LDL cholesterol ("bad" cholesterol) while supporting a beneficial increase of HDL cholesterol ("good" cholesterol). This systematic modification of blood fats is the core function of the medicine and is essential for achieving the therapeutic goal of managing lipid levels associated with dyslipidemia.

Regulatory References

Fenofibrate Monograph

What side effects are possible with Грофибрат?

Possible Side Effects and Safety Information

The safety profile of Грофибрат (Fenofibrate) is formally established by regulatory agencies like the FDA and EMA based on clinical trial data. Adverse reactions are classified by frequency and grouped according to the physiological system affected, providing a structured understanding of potential risks.

Frequency-Classified Adverse Reactions

The most frequently documented side effects are categorized as Common, affecting primarily the Gastrointestinal system and Hepatobiliary system (liver). Common reactions include elevated liver transaminases (AST/ALT), elevated plasma homocysteine levels, and gastrointestinal symptoms such as abdominal pain, nausea, and flatulence.

Events classified as Uncommon include pancreatitis, thromboembolism (e.g., deep vein thrombosis, pulmonary embolism), myalgia, myositis, and hypersensitivity reactions. Rare, but clinically significant, reactions include rhabdomyolysis (severe muscle breakdown) and hepatitis.

Serious Safety Considerations and Restrictions

The official labeling documents certain serious adverse reactions, notably Rhabdomyolysis and Thromboembolic events, which warrant specific regulatory mention. The safety profile also includes mandatory restrictions regarding use in certain patient populations or pre-existing conditions.

The medication is formally contraindicated in patients with severe renal impairment, established hepatic dysfunction (including biliary cirrhosis), and pre-existing gallbladder disease. Safety and effectiveness have not been established for use in pediatric patients. Furthermore, regulatory documents note that elevations in liver enzymes are often transient and may occur primarily at the initiation of therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Fenofibrate (the active ingredient in Грофибрат) outlines specific required emergency actions and supportive management procedures in the event of an overdose.

Immediate Emergency Action

You must seek emergency medical attention immediately if an overdose is suspected or confirmed.

Overdose Management Profile

Regulatory guidance confirms that there is no specific treatment or antidote known for Fenofibrate overdose. Therefore, treatment focuses on supportive care and the removal of the unabsorbed substance from the body, as outlined below:

Management Measure	Requirement Stated in Official Documents
Symptom Documentation	No specific clinical signs or symptom profiles are formally listed in the Overdosage sections of regulatory labels.
Supportive Care	General supportive care is indicated, including the monitoring of vital signs and observation of clinical status under medical supervision.
Drug Removal	Elimination of unabsorbed drug should be achieved by emesis (inducing vomiting) or gastric lavage (stomach wash), if medically indicated. Usual precautions must be observed to maintain the airway during these procedures.
Procedural Limitation	Hemodialysis should not be considered for drug removal because the active metabolite, fenofibric acid, is highly bound to plasma proteins.

These statements define the regulatory approach to managing an overdose, mandating immediate medical intervention and prescribing necessary supportive measures despite the lack of a known antidote. The instructions ensure that necessary steps are taken to address potential systemic impact and enhance the elimination of the product from the body.

Therapeutic Uses of Грофибрат

What Грофибрат Treats: Main Uses and Benefits

Грофибрат (referring to the fibrate class of medication) is relevant in contexts marked by dyslipidemia, applied across domains where additional symptomatic support is needed for managing symptoms related to high levels of fats in the blood. This medicine is commonly used in conjunction with lifestyle adjustments for managing specific lipid conditions, including severe hypertriglyceridemia and mixed dyslipidemia. The therapeutic domains are relevant in clinical settings marked by temporary physiological imbalance.

Supporting Healthy Blood Fat Levels

This medication is relevant in contexts marked by systemic imbalance (abnormal cholesterol and/or triglyceride levels). It helps address groups of symptoms that may appear suddenly or intensify over time, assisting with maintaining functional stability and contributing to improved day-to-day comfort during symptomatic periods.

Management of Severe Lipid Conditions

The medicine is commonly used across conditions presenting with acute episodes characterized by periods of markedly elevated serum triglycerides. It is relevant in conditions where symptoms may intensify temporarily, providing support that helps ease the overall symptom burden.

Quick Fact: Relevant for Easing Systemic Imbalance

Addressing Mixed Cholesterol and Triglyceride Issues

Applied across domains where additional symptomatic support is needed, this medicine is also relevant for patients with high LDL-C and high triglycerides. It offers symptomatic relief that may help patients cope more steadily with symptom fluctuations, and supports the patient during difficult episodes by easing distress.

Eligibility and Restrictions for Use

Who can and cannot use Грофибрат? — Official Regulatory Information

Use of Грофибрат (Fenofibrate) is governed by specific population eligibility rules defined in official regulatory documents, focusing on organ function, age, and physiological state.

Population Status	Regulatory Rule
Contraindicated	Use is strictly forbidden for patients with severe renal impairment (e.g., eGFR <30 mL/min/1.73 m^2), active liver disease, or pre-existing gallbladder disease. It is also contraindicated for nursing mothers and those with known hypersensitivity to the drug or related substances.
Use Restricted	The medicine is restricted for patients with mild to moderate renal impairment and requires dose reduction and careful monitoring. Use during pregnancy is conditional and only permitted if the potential benefit justifies the risk, due to a lack of sufficient human data.
Age-Group Rules	Adults are the approved population. Safety and efficacy have not been established in pediatric patients (younger than 18 years), where use is not recommended. In older adults, use is conditional on the assessment of their kidney function.

Summary: Official regulations strictly limit Грофибрат to the adult population, with absolute prohibitions against use in severe organ failure states (liver, kidney, gallbladder) and during lactation. Any allowance for use outside of standard eligibility, such as in mild renal impairment, is conditional and strictly managed.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Грофибрат primarily through constraints on co-administration risks and pharmacokinetic behavior. The following substances are officially documented as interacting:

Interacting Substance	Regulatory Outcome & Constraint
HMG-CoA Reductase Inhibitors (Statins)	Avoid combination due to increased, documented risk of myopathy and rhabdomyolysis.
Coumarin Anticoagulants (e.g., Warfarin)	Potentiation of effect (prolonged PT/INR) requiring mandated dosage reduction and frequent monitoring.
Colchicine & Other Fibrates	Documented increased, additive risk of myopathy and rhabdomyolysis.

Interacting Substance/Condition	Pharmacokinetic/Timing Requirement
Bile-Acid Binding Resins	Mandatory separation is required: administer Грофибрат 1 hour before or 4–6 hours after the resin to avoid reduced absorption.
Immunosuppressants	Co-administration risks deterioration of renal function. Risk of muscle toxicity is also heightened in elderly patients and those with renal impairment.
Food	Administration with food enhances the absorption and bioavailability of the medicine.

These official statements establish clear constraints, including mandatory administration timing rules and combinations that regulatory authorities advise should be avoided or used only with strict monitoring of lab parameters.

Mechanism of Action

Nuclear Receptor-Mediated Gene Control

The mechanism of action is driven by Fenofibric acid, the active metabolite, which acts as a specific agonist for the Peroxisome Proliferator-Activated Receptor alpha ( PPARalpha) . This nuclear receptor activation initiates a sequence of events that alters the gene transcription for key proteins, modulating the metabolic machinery of the liver and muscle. This process is key, as it involves control over the synthesis rates of critical enzymes and apolipoproteins that regulate lipid metabolism.

Enhanced Catabolism and Clearance of Triglycerides

By upregulating the fat-clearing enzyme Lipoprotein Lipase ( LPL) and simultaneously suppressing its inhibitor, Apolipoprotein C-III ( ApoC-III), Грофибрат enhances the catabolism of triglyceride-rich particles ( VLDL and chylomicrons). This mechanism leads to the clearance of triglycerides from the bloodstream and limits the precursors available for forming small, dense LDL particles.

Lipoprotein Remodeling and HDL Component Synthesis

The PPARalpha mechanism also promotes the synthesis of structural components like Apolipoprotein A-I ( ApoA-I), a primary building block of HDL cholesterol. This specific modulation causes a functional shift in lipoprotein composition, which facilitates the physiological process of reverse cholesterol transport and contributes to the modification of circulating lipid components.

Dosage and Administration Information

Administration and Dosing Instructions

Грофибрат (Fenofibrate) is administered via the oral route using specialized tablets or capsules and should be taken once daily. To ensure the proper release of the medicine, tablets and capsules must be swallowed whole and must not be crushed, dissolved, or chewed.

Standard Dosing Regimens

Adult dosing is product-specific, typically ranging between 120 mg and 160 mg once daily for primary hyperlipidemia. For severe hypertriglyceridemia, initial doses may range from 40 mg to 145 mg once daily. The maximum recommended dose is generally 145 mg or 160 mg once daily, depending on the formulation.

Indication	Standard Adult Daily Dose Range	Maximum Daily Dose
Primary Hyperlipidemia / Mixed Dyslipidemia	120 mg to 160 mg once daily	160 mg once daily
Severe Hypertriglyceridemia	40 mg to 145 mg once daily	145 mg once daily

Procedural and Population Rules

Timing and Concomitant Use: While some formulations may be taken with or without food, other specialized products require administration with a meal to optimize absorption. If also taking a bile acid binding resin, Грофибрат must be taken at least one hour before or four to six hours after the resin. If a dose is missed, patients should not take an extra dose but resume treatment with the next scheduled dose.

Dose Adjustment: Dosage is adjusted based on patient response, following repeat lipid determinations at 4- to 8-week intervals. If an adequate response is not achieved after two to three months of treatment at the maximum dose, discontinuation is recommended.

Special Populations: Dose reduction is required for patients with mild to moderate renal impairment (e.g., an initial dose of 40 mg to 54 mg once daily), and use is avoided in severe renal impairment. In older adults, dose selection is based on kidney function.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Грофибрат (Fenofibrate)

The research into the active ingredient in Грофибрат focuses on understanding how the substance was observed alongside blood fat levels and monitoring its long-term impact on patient outcomes. This summary reflects what types of studies have been conducted and what patterns the research has so far described.

Evidence for Management of Severe Blood Fat Imbalances (Hypertriglyceridemia)

Research here primarily involves short-term Randomized Controlled Trials (RCTs) examining adults with very high triglycerides (often ge 500 mg/dL). Researchers examined how the substance related to circulating Triglycerides and VLDL levels. Studies consistently reported patterns of change in plasma Triglyceride levels measured during short-term observation. The evidence primarily focuses on biomarker modification, and the long-term impact on clinical events in this specific high-triglyceride population remains uncertain.

Evidence for Use in Combined Cholesterol and Triglyceride Issues (Mixed Dyslipidemia)

Large-scale RCTs were evaluated in adults with mixed dyslipidemia to monitor changes in LDL-C, HDL-C, and Triglyceride levels, and also monitored the occurrence of Major Adverse Cardiovascular Events (MACE). Findings related to MACE across the entire study population were mixed. The difference in research findings was most consistently observed in the specific subgroup of patients who started the study with both high triglycerides and low HDL-C.

Evidence for Use in Diabetic Microvascular Conditions

Research in this area was observed in secondary analyses of long-term RCTs, including adults with Type 2 Diabetes. Researchers monitored outcomes related to the rate of required laser treatment for diabetic retinopathy and the progression of albuminuria (a kidney marker). One large-scale study reported patterns related to these outcomes. These findings are primarily drawn from secondary analyses, meaning they were not the single, predefined main goal of the largest trials.

Long-Term Studies, Specific Groups, and Uncertainty

The most substantial evidence regarding long-term outcomes comes from trials with follow-up durations of 4 to 5 years, which provided the necessary duration of observation. Research was evaluated in the broad population of adults, with specific focus on those with Type 2 Diabetes. The main uncertainty relates to the mixed findings regarding general MACE reduction across the total study population. Data for certain groups, such as long-term outcomes for those outside specific high-risk subgroups, remain insufficient.

Key Studies & References

FENOFIBRATE tablet - DailyMed - NIH

Frequently Asked Questions (FAQ)

Common questions about Грофибрат (FAQ)

Q: How long does it typically take to see the effects of Грофибрат?

The effects of Грофибрат on blood fat levels are monitored over time. According to regulatory documents, dose adjustments are often based on repeat blood fat level determinations taken at 4- to 8-week intervals after starting treatment. This regular testing is used to assess the response to the medicine and confirm the therapeutic goal is being achieved.

Q: Can I take Грофибрат if I already take a vitamin supplement?

Official product labeling focuses on interactions with specific prescription drugs and bile acid resins. It notes an interaction with Vitamin K antagonists, which are sometimes found in high-dose vitamin combinations, requiring careful monitoring. Official documents do not explicitly mention specific interactions for most other general vitamin supplements.

Q: What should I know about taking Грофибрат with alcohol?

Regulatory information emphasizes that Грофибрат is strictly contraindicated, or forbidden, in patients with active liver disease. Because the medicine is contraindicated in patients with active liver disease, information on alcohol use is relevant to the overall risk profile. In addition, alcohol can potentially increase blood fat levels, which may lessen the beneficial effects of the medicine on your lipid profile.

Q: How does Грофибрат fit into a complete treatment plan?

Грофибрат is indicated as an adjunctive therapy, meaning it is intended to be used alongside other treatments. Official guidance states that patients should be placed on an appropriate fat-lowering diet before starting and while using the medicine. The official approach involves using the medicine with lifestyle considerations, such as a fat-lowering diet, exercise, and weight reduction.

Q: Is it possible to develop a tolerance to Грофибрат over time?

Official documents do not use the term 'tolerance' to describe the medication's effects. However, they recommend that if an adequate response in blood fat levels is not achieved after two to three months of treatment at the maximum dose, discontinuation should be considered. This process ensures that the treatment remains clinically effective for the patient.

Q: What is the difference between a common side effect and a serious one for Грофибрат?

Side effects are classified by their frequency and severity in official documents. Common reactions, such as mild gastrointestinal symptoms or headache, occur more often but are generally less critical. Serious adverse reactions, like rhabdomyolysis (severe muscle breakdown) or thromboembolism, are specifically noted in Warnings and Precautions and are clinically significant events that warrant attention.

Q: What are the most frequent reasons people stop taking Грофибрат in studies?

Based on regulatory guidance, people may stop taking Грофибрат for two main reasons. The first is if blood fat levels do not show an adequate response after a specified monitoring period. The second is if a patient experiences or develops a suspected serious safety issue, such as severe muscle problems.

Q: Does the effectiveness of Грофибрат change over time?

Regulatory guidelines require monitoring of a patient’s lipid levels at regular intervals, typically every 4 to 8 weeks, to ensure that the medication is maintaining its desired effectiveness. This continuous assessment is necessary to confirm that the patient's blood fat profile remains adequately managed throughout the treatment course.

Q: Is Грофибрат the same as other medicines used for similar conditions?

Грофибрат belongs to a specific class of drugs called fibric acid derivatives, or fibrates. While it is used to regulate fat levels, like other medicines in the lipid-regulating agent category, it has a distinct chemical structure and mechanism of action compared to different classes of medication. It may be used as an alternative when other options are not appropriate.

Q: Is Грофибрат a controlled substance or addictive?

According to official information, Грофибрат is classified only as a prescription-only medication. It is not listed as a controlled substance by regulatory agencies and is not generally associated with potential for abuse or dependence.

Q: Can a person stop taking Грофибрат suddenly?

Official guidelines describe situations when treatment should be stopped, such as inadequate effectiveness or the suspicion of serious muscle issues. The medicine is not typically known to cause withdrawal symptoms upon cessation. Treatment decisions are managed by the prescribing healthcare provider.

Q: Are there any limitations on driving while taking Грофибрат?

Official adverse reaction reports include central nervous system effects such as dizziness and headache. Patients who experience these types of reactions while using Грофибрат should be aware that official guidelines state that caution is necessary when operating machinery or driving if these reactions occur.

Q: How quickly does Грофибрат leave the system after the last dose?

The active component of the medicine, fenofibric acid, is cleared from the body at a measurable rate. According to official product information, the half-life—the time it takes for half of the substance to be removed—is approximately 20 hours in people with healthy kidney function.

Q: Are there specific risks associated with stopping Грофибрат treatment?

The primary risk noted is that stopping the medication due to an inadequate lipid-lowering response will cause the patient's blood fat levels (cholesterol and triglycerides) to return to the elevated state that the medicine was intended to manage. While official documents do not mention withdrawal effects, the health risks associated with uncontrolled elevated fat levels are a long-term concern.

Q: How is Грофибрат different from a placebo in clinical trials?

In clinical trials, researchers observed specific patterns of change in patients taking Грофибрат compared to those taking a placebo (an inactive substance). These observed patterns related to changes in key blood fat levels, such as triglycerides, VLDL (very low-density lipoprotein), and HDL (high-density lipoprotein) components.

Q: Are there specific criteria for who is eligible to start Грофибрат?

The medicine is officially indicated for use in adults with specific lipid conditions, such as severe hypertriglyceridemia or mixed hyperlipidemia. Before treatment begins, regulatory information specifies that the patient's condition is diagnosed and the use of an appropriate fat-lowering diet is initiated.

Q: If I feel better, can I assume Грофибрат is working?

The conditions Грофибрат addresses, such as high cholesterol and triglycerides, are often without noticeable symptoms. Therefore, a feeling of wellness is not a reliable indicator of the medicine's effectiveness. Official guidance states that the effectiveness of the medication must be determined by objective, repeat blood tests to monitor lipid levels.

Q: Is Грофибрат available over the counter?

No, according to official classification and Quick Facts, Грофибрат is a prescription-only medication. It must be prescribed by an authorized healthcare provider.

Q: Does the time of day I take Грофибрат matter?

Regulatory information states that Грофибрат is intended to be taken once daily. While some specific formulations are advised to be taken with a meal to ensure optimal absorption, the medicine can generally be administered as a single dose at any time of day, provided the patient maintains consistency.

How should Грофибрат be stored and disposed of?

Storage and Disposal of Fenofibrate

Fenofibrate must be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), and should not exceed 30 C. The medicine requires protection by storing it away from excess heat, moisture, and light. It must be kept in the original container, maintained tightly closed.

To ensure safety, Fenofibrate must be kept out of the sight and reach of children, often requiring the use of locked safety caps. Disposal of unused or expired product must be done in accordance with local, regional, and national requirements. The product should not be released into the environment or allowed to enter drains or wastewater.

Грофибрат